KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Current Leases (2016 - 2018)

Vertex Pharmaceuticals (VRTX) has 7 years of Current Leases data on record, last reported at $9.8 million in Q4 2018.

  • For Q4 2018, Current Leases fell 56.43% year-over-year to $9.8 million; the TTM value through Dec 2018 reached $9.8 million, down 56.43%, while the annual FY2018 figure was $9.8 million, 56.43% down from the prior year.
  • Current Leases reached $9.8 million in Q4 2018 per VRTX's latest filing, down from $11.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $22.5 million in Q4 2017 and bottomed at $9.8 million in Q4 2018.
  • Average Current Leases over 5 years is $17.2 million, with a median of $17.8 million recorded in 2014.
  • Peak YoY movement for Current Leases: surged 120.71% in 2014, then plummeted 56.43% in 2018.
  • A 5-year view of Current Leases shows it stood at $17.8 million in 2014, then decreased by 12.7% to $15.5 million in 2015, then rose by 24.97% to $19.4 million in 2016, then grew by 15.98% to $22.5 million in 2017, then tumbled by 56.43% to $9.8 million in 2018.
  • Per Business Quant database, its latest 3 readings for Current Leases were $9.8 million in Q4 2018, $11.5 million in Q3 2018, and $16.9 million in Q1 2018.